Glumet
RX

Glumet

Glumet

Glumet are tablets that are prescribed to patients with type II diabetes mellitus as mono or combination therapy and to reduce complications for overweight adults as a drug after ineffective diet therapy. The active substance is metformin. You can read more about Glumet in the instructions.

Information

Indications for use (instruction): Glumet

Type 2 diabetes with poor diet and exercise regimen, especially in overweight patients;

  • as monotherapy or combination therapy with other oral hypoglycemic agents or with insulin for the treatment of adults;
  • as monotherapy or combination therapy with insulin for the treatment of children aged 10 years and adolescents.

To reduce the complications of diabetes in adult patients with type 2 diabetes and overweight as a first-line drug after ineffective diet therapy.

How to use

Adult patients with normal renal function (GFR ≥ 90 ml/min)

Monotherapy or combination therapy with other oral hypoglycemic agents

Typically, the starting dose is 500 mg or 850 mg (glumet, film-coated tablets, 500 mg or 850 mg) 2–3 times a day during or after meals.

After 10–15 days, the dose should be adjusted according to the results of serum glucose measurements.

A slow increase in the dose helps to reduce the side effects of the digestive tract.

In the treatment with high doses (2000–3000 mg per day) it is possible to replace every 2 tablets of Glumet preparation, 500 mg, for 1 tablet of Glumet preparation, 1000 mg.

The maximum recommended dose is 3000 mg per day, divided into 3 doses.

If you switch from another antidiabetic agent, you must stop taking it and prescribe metformin as above.

Combination therapy with insulin

For better blood glucose control, metformin and insulin can be used as combination therapy. Typically, the starting dose is 500 mg or 850 mg of metformin hydrochloride 2-3 times a day, while the insulin dose should be selected according to blood glucose measurements.

Elderly patients may have decreased renal function, so metformin dose should be selected based on an evaluation of renal function, which should be done regularly.

Kidney failure. GFR should be evaluated before treatment with metformin containing medicinal products and at least annually after initiation of treatment. Patients at increased risk of further progression of renal failure and elderly patients should be monitored as closely as possible for kidney function as often as possible, for example, every 3-6 months.

Children

Monotherapy or combination therapy with insulin

Glyumet is for use in children aged 10 years and adolescents. Typically, the starting dose is 500 mg or 850 mg of Glumet 1 time a day during or after a meal. After 10–15 days, the dose should be adjusted according to the results of serum glucose measurements.

A slow increase in the dose helps to reduce the side effects of the digestive tract.

The maximum recommended dose is 2000 mg per day, divided into 2–3 doses.

Contraindications

  • hypersensitivity to metformin or to any other component of the drug;
  • any type of acute metabolic acidosis (eg, lactic acidosis, diabetic ketoacidosis);
  • diabetes mellitus;
  • severe renal failure (glomerular filtration rate (GFR) <30 ml/min);
  • acute conditions that run with the risk of developing kidney dysfunction, such as: dehydration, severe infectious diseases, shock;
  • diseases that can lead to the development of tissue hypoxia (especially acute illnesses or exacerbations of chronic disease): decompensated heart failure, respiratory failure, recent myocardial infarction, shock;
  • liver failure, acute alcohol poisoning, alcoholism.

Composition

Active ingredient: metformin hydrochloride;

  • 1 film-coated tablet of 500 mg contains 500 mg of metformin hydrochloride corresponding to 390 mg of metformin;
  • 1 film-coated tablet of 850 mg contains 850 mg of metformin hydrochloride corresponding to 662.9 mg of metformin;
  • 1 film-coated tablet of 1000 mg contains 1000 mg of metformin hydrochloride corresponding to 780 mg of metformin.

Excipients: povidone, polyethylene glycol 6000, sorbitol (E 420), magnesium stearate.

Film coating: Opadry Y-1-7000 (hypromellose, titanium dioxide (E 171), polyethylene glycol), paraffin solid.

Release form

Film-coated tablets, 500 mg or 850 mg: 10 tablets in a blister; 10 blisters per carton.

Film-coated tablets, 1000 mg: 10 tablets in a blister; 6 blisters in a carton.

Storage conditions

Store in the original package at a temperature not exceeding 25 °C. Keep out of the reach of children.

Manufacturer

TPI Norway AU, Groveveien 1, KRAGERO, No-3770, Norway.

Registration certificate

No.942 dated 05/16/2018
Registration certificate: No. UA/16347/01/01

Information on medicines is intended exclusively for doctors.